Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Two other inhibitors are in clinical trials for oncogenic MET cancers (TPX-0022) and RET driven cancers (TPX-0046). Turning Point Therapeutics is driven to develop therapies that mark a turning point for patients in their cancer treatment.
We are seeking a highly motivated individual to join Turning Point Therapeutics as a Clinical Pharmacology Lead (Associate Director to Director level). The clinical pharmacology lead will be an integral member of the multidisciplinary team and is responsible for leading the clinical pharmacology support to Turning Point Therapeutics transformative oncology assets.
Represent clinical pharmacology discipline on cross-functional project teams involving the clinical development of candidate drug products.
Collaborate with biostatisticians, clinicians, and clinical operations colleagues for the optimal design of Phase I-IV studies; contribute to the clinical study protocols and reports.
Provide scientific leadership in clinical pharmacology studies.
Assist in integrating and interpreting nonclinical and clinical pharmacology, DMPK, and translational medicine knowledge; lead modeling & simulation (PK/PD) activities in the clinical and clinical pharmacology programs.
Preparation of clinical pharmacology summaries and regulatory documents (IND, IMPD, IB, NDA CTD, etc). Participate in drafting publications and making scientific presentations consistent with development strategies.
A Pharm. D., or Ph.D. degree in relevant disciplines with 3+ years of industrial experience as a clinical pharmacologist. The level will be depending on experience.
Broad working knowledge in clinical pharmacology with strong expertise in PK, PK/PD, and small molecule DMPK science.
Hands-on experience in PK/PD modeling & simulation using WinNonlin, NONMEM, R, and potentially other data analysis software.
Track record of contribution to project teams enabling achievement of milestones in a time-efficient manner.
Turning Point Therapeutics is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability, or veteran status. Turning Point Therapeutics also complies with all applicable national, state, and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Turning Point Therapeutics is an E-Verify employer.
Employer will assist with relocation costs.
Internal Number: 71
About Turning Point Therapeutics
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, Repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Turning Point Therapeutics is driven to develop therapies that mark a turning point for patients in their cancer treatment.